Welcome & Introductions

As the esteemed Director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute, Dr. Omid Hamid dedicates his expertise to ensuring patients have access to the latest therapeutic advances. Recently, within the Phase 1 Developmental Therapeutics Program, Dr. Hamid has played a pivotal role in transitioning new treatments from research to clinical application, significantly benefiting patients. His work focuses on Immuno-Oncologic therapies, including PD-1 inhibitors (such as Keytruda, Nivolumab, Atezolizumab), other checkpoint inhibitors, anti-angiogenesis treatments, and targeted agents that disrupt tumor cell functions (like braf, mek). Dr. Hamid's research primarily aims at harnessing the immune system to combat cancer cells, striving for sustained high levels of immunity and the discovery of innovative treatments. His investigations, initially centered on melanoma, now span across groundbreaking trials for various cancers.
Nationally and internationally, Dr. Hamid is celebrated as a leading expert in Immuno-Oncologic Drug Development and Melanoma Therapeutics. As the Chief of Immunotherapy and Translational Research at The Angeles Clinic, his leadership has ushered in groundbreaking, first-in-class drugs, transforming patient care. Dr. Hamid contributed significantly to the initial trials of transformative agents like Ipilimumab, Pembrolizumab, Nivolumab, Atazolizumab, and Vemurafenib, which have markedly improved patient survival. Under his guidance, patients now have access to the next generation of treatments, including combinations of BRAF/MEK inhibitors and innovative immunotherapies with PD-1 antibodies. Currently, Dr. Hamid spearheads the development of Next-Generation Checkpoint Inhibitors, focusing on anti-OX40, 41BB, GITR antibodies, and pioneering T-cell adoptive therapies and bispecific antibodies.
Dr. Hamid's groundbreaking research has been showcased at premier national and international forums, including the American Society of Clinical Oncology (ASCO) and the Society for Melanoma Research, among others. His contributions to the field are well-documented in prestigious journals such as the Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), and Clinical Cancer Research, featuring a broad array of manuscripts, abstracts, and reviews on immunotherapy, targeted therapy, and melanoma care.